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ABSTRACT: Gluco-azoles competitively inhibit glucosidases 
by transition-state mimicry and their ability to interact with cata-
lytic acid residues in glucosidase active sites. We noted that no 
azole-type inhibitors described, to date, possess a protic nitrogen 
characteristic for 1H-imidazoles. Here, we present gluco-1H-
imidazole, a gluco-azole bearing a 1H-imidazole fused to a gluco-
pyranose-configured cyclitol core, and three close analogues as 
new glucosidase inhibitors. All compounds inhibit human retain-
ing ȕ-glucosidase, GBA1, with the most potent ones inhibiting 
this enzyme (deficient in Gaucher disease) on a par with glucoim-
idazole. None inhibit glucosylceramide synthase, cytosolic ȕ-
glucosidase GBA2 or Į-glucosidase GAA. Structural, physical 
and computational studies provide first insights into the binding 
mode of this conceptually new class of retaining ȕ-glucosidase 
inhibitors. 
Glycosidases catalyze the hydrolysis of interglycosidic linkag-
es, and glycosidase inhibitors are widely regarded as promising 
therapeutic entities.1 Azole-containing glycopyranoside mimics 
are a major class of competitive glycosidase inhibitors.2 The 
natural product, nagstatin (1), is a potent N-acetyl-ȕ-D-
glucosaminidase (NAG) inhibitor.3 Glucopyranose mimics bear-
ing tetrazole (2), triazole (3, 4) and imidazole (5) moieties have 
been conceived as ȕ-glucosidase inhibitors by Tatsuta and 
Vasella, with inhibitory potencies against sweet almond ȕ-
glucosidase ranging from low nanomolar (5) to high micromolar 
(4, Figure 1a).47 The reaction itinerary followed by many ȕ-
glucosidases proceeds via a 4H3 transition state conformation,8 
matching one of the thermodynamically most favored confor-
mations of gluco-azoles (local minima calculated for 5 are 4H3 
and 3H4).9 This conformational transition state mimicry contrib-
utes considerably to the inhibitory potency of gluco-azoles. 
Vasella concluded, from extensive studies on gluco-azoles (in-
cluding compounds 2-5), that an azole nitrogen at the position 
corresponding to the exocyclic oxygen in a ȕ-glucoside substrate 
is essential for inhibitory potency, as this exocyclic nitrogen 
participates in lateral coordination with the catalytic acid/base of 
anti-protonating glucosidases.1014 Remarkably, no azole-type 
inhibitors synthesized to date are protic with respect to the azole 
ring (such as 1H-imidazoles), and we reasoned that such position-
al isomers would be attractive alternatives to the reported gluco-
azoles. Herein, we report on the synthesis and biochemical eval-
uation of gluco-1H-imidazole 6 and its analogues 7-9 as concep-
tually new retaining ȕ-glucosidase inhibitors (Figure 1b). 
Figure 1. (a) Known cyclitol-azole type glycosidase inhibitors 
and their inhibitory potencies against porcine NAG (1)3 and sweet 
almond ȕ-glucosidase (2-5).47 (b) 1H-Imidazoles subject of this 
study. 
The synthesis of gluco-1H-imidazole 6 commenced with cyclo-
hexene 10,15 which was transformed into the vicinal diamine 
following a modified procedure from Llebaria.16 Rapid conver-
sion of 10 was accomplished using RuCl3/NaIO4, affording a 
separable, near equimolar mixture of 1,2-cis-dihydroxy isomers 
11a (S,S) and 11b (R,R).17 Bismesylation and subsequent azide 
substitution afforded diazido cyclitols 12a,b. Platinum oxide 
catalyzed hydrogenolysis afforded diamino cyclitols 13a,b, which 
were condensed with trimethyl orthoformate in hexafluoroisopro-
panol (HFIP) to afford imidazolines 14a,b.18 Protected 1H-
imidazole 15 was obtained by oxidation of either isomer of 14 
with IBX/DMSO,19 and final hydrogenolysis afforded gluco-1H-
imidazole 6. Derivatization of the imidazole ring of gluco-1H-
imidazoles was achieved by variation of the trimethyl orthoester 
employed. Thus, reaction of 13a,b with trimethyl orthovalerate 
followed by oxidation and deprotection furnished 2-butyl-1H-
imidazole 7 via 16a,b and 17. Utilizing tetrabenzyl myo-
diaminocyclitol16 as starting material yielded conduritol B-1H-
imidazoles 8 and 9 (see Supporting Information (SI)). 
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Scheme 1. Synthesis of 1H-imidazoles 6 and 7.a 
aReagents and conditions: a) RuCl3á3H2O (7 mol%), NaIO4, 
EtOAc, MeCN, H2O, 0 °C, 90 min, 11a 40%, 11b 32%; b) MsCl, 
N-methyl-imidazole, Et3N, CHCl3, rt, 16 h, then NaN3, DMF, 100 
°C, 16 h, 12a 74%, 12b 58%; c) PtO2, H2, THF, rt, 16 h, 13a 80%, 
13b 96%; d) trimethyl orthoformate, HFIP, rt, 16h, 14a 76%, 14b 
87%; or trimethyl orthovalerate, HFIP, rt, 16 h, 16a 74%, 16b 
78%; e) For 15: IBX, DMSO, 45 °C, 16 h, 75% from 14a, 71% 
from 14b; for 17: (COCl)2, DMSO, DCM, -60 °C, 1h, 76% from 
16a; 70% from 16b; f) Pd(OH)2/C, H2, HCl, MeOH, quant. 6; 
quant. 7.  
We determined competitive kinetic constants and IC50 values 
for 1H-imidazoles 69 as compared with glucoimidazole 5 for 
inhibition of the retaining glucosidases TmGH1 from Thermotoga 
maritima,20 TxGH116 from Thermoanaerobacterium xylanolyti-
cum,21 sweet almond ȕ-glucosidase (GH1), human lysosomal acid 
ȕ-glucosylceramidase (GBA1, GH30), human cytosolic ȕ-
glucosylceramidase (GBA2, GH116), murine glucosylceramide 
synthase (GCS) and human acid Į-glucosidase (GAA, GH31). 
Gluco-1H-imidazole 6 displayed micromolar inhibitory activity 
against most ȕ-glucosidases tested, with Ki values ranging from 
~3.9 µM against GBA1 to ~69 µM against TxGH116 (Table 1). 
Remarkably, given their apparent structural similarity, 1H-
imidazole 6 proved to be a weaker ȕ-glucosidase inhibitor than 
glucoimidazole 5, which inhibited ȕ-glucosidases at nanomolar 
concentrations. Attachment of a butyl moiety, as in 7, increased 
the inhibitory potency of the gluco-1H-imidazole scaffold. Whilst 
this increase in potency was modest for TmGH1 and TxGH116, 7 
inhibited sweet almond ȕ-glucosidase and GBA1 with nanomolar 
potency. Notably, the biological role of GBA1 is breakdown of 
amphiphilic glucosylceramide.22 Conduritol-1H-imidazole 8 did 
not effectively inhibit any glucosidases tested except for GBA1, 
consistent with a loss of interactions at the O6 position, but also 
with the fact that GBA1 is effectively inhibited by conduritol B 
epoxide (CBE).23 As with the gluco-1H-imidazoles, addition of a 
butyl moiety to the conduritol-1H-imidazole scaffold increased 
activity against sweet almond ȕ-glucosidase and GBA1, rendering 
9 a nanomolar inhibitor of these enzymes. No compounds dis-
played any inhibitory activity against GBA2, GCS or Į-
glucosidase GAA under our assay conditions. Competitive, selec-
tive GBA1 inhibitors are considered attractive starting points for 
the development of pharmacological chaperones: compounds that 
stabilize the fold of mutant, partially malfunctioning GBA1 in 
Gaucher patients.24,25 Compounds 7 and 9 (as well as known 
glucoimidazole 5) are in our opinion attractive starting points for 
this purpose. 
One striking result displayed in Table 1 is that 1H-imidazole 6 
is a comparatively much weaker retaining ȕ-glucosidase inhibitor 
than glucoimidazole 5. Since the structures are closely related, we 
elected to investigate this result in more depth. Literature studies 
have shown that the inherent basicity of the azole ring in com-
pounds 2-5 correlates to the inhibitory potency.26 Basicity plays a 
negligible role here, since the experimental pKAH values of 5 and 
6 are almost identical (5: pKAH  6.2, lit. 6.126; 6: pKAH  6.0; Figure 
S1, S2). We also explored the interaction of gluco-1H-imidazoles 
with TmGH1 and TxGH116 by isothermal titration calorimetry 
(ITC) at pH 5.8 (activity optimum11,21) and pH 6.8 (where 5 
shows strongest inhibition)11. In line with the Ki data (Table 1), 
ITC titrations at both pH values showed nanomolar binding affini-
ties for 5, and micromolar affinities for 6 and 7 (Table S3). The 
enthalpic contributions in active site binding for 1H-azoles are 
smaller than those observed for 5, and only partially compensated 
for by increased entropic contributions to the binding energy. In 
line with what has been reported for 5,11 the presence of a hydro-
phobic moiety in 7 reduced its enthalpy of binding compared to 6, 
which was counterbalanced by an increase in favorable entropic 
contributions to binding. 
Table 1. Inhibition constants (Ki) and IC50 values in µM for compounds 5-9. 
 TmGH1a TxGH116a sweet almond 
GH1b 
GBA1a GBA2c GCS c GAAc 
6 58 ± 1 69 ± 12 23 ± 1 3.9 ± 2 >100 >50 >100 
7 39 ± 14 46 ± 5 0.039 ± 0.006 0.133 ± 0.040 >100 >50 >100 
8 >100c >100c >100c 13.7 ± 6 >100 >50 >100 
9 >100c >100c 0.221 ± 0.004 0.079 ± 0.001 >100 >50 >100 
5 0.026 ± 0.001 0.165 ± 0.006 0.067 ± 0.004d 0.070 ± 0.005 >100 >50 >100 
Values are mean ± SD from triplicate experiments. Assays measured at apH 6.8 using ȕ-p-NPG substrate; bpH 5.2 using ȕ-2,4-
DNPG substrate; cApparent IC50. 
dLit. Ki = 0.100 µM.6  
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Next, the X-ray structure of 6 in complex with TmGH1 was de-
termined to 1.7 Å (PDB: 5OSS), and compared to the  structure of 
the same enzyme complexed with 5 (PDB: 2CES).11 These struc-
tures revealed the binding mode of both compounds to be similar. 
We observed a single molecule of 6 in the active site after ligand 
soaking, adopting a 4E conformation, similar to the complex of 5 
and TmGH1 (Figure 2a).11 H-bonding interactions made by 6 to 
active site residues were identical to those observed with 5, albeit 
with a slight upwards tilt for 6 compared to 5 (~0.4 or 0.5 Å 
upward shifts at the apical imidazole carbon, compared with 
ligands in chains A or B of 2CES respectively; Figure 2b, Figure 
S3). Crystal structures in TxGH116 at 2.1 Å resolution (Figure 
2c,d) also revealed similar binding modes21 and a ~0.5 Å up-
wards tilt for 6 compared to 5 (PDB: 5OST and 5BX4, respec-
tively). For both TmGH1 and TxGH116 complexes, B-factors in 
the imidazole portion of 6 were markedly higher when com-
pared to the glucose portion of the molecule, indicating the 
imidazole of 6 was more disordered in the crystal structure and 
may be bound less strongly.  No strong B-factor trend was ob-
served for complexes with 5 (Figure S3). 
The underlying cause for the reduced potency of gluco-1H-
imidazole 6 compared to 5 is most likely the combination of a 
number of factors. We propose that repositioning of the N1 atom 
(from the bridgehead position in 5 to the position in 6) brings two 
major consequences that together reduce the binding affinity of 6 
compared to 5. Firstly, considering the situation where the imid-
azole is in a neutral state28: the free lone pair of the N2 atom in 5 
can laterally coordinate to the acid/base residue of the bound 
glucosidase in typical anti-protonating glucosidases14 (although 
TxGH116 lacks this interaction due to the unusual placement of 
its acid/base residue21). This lateral positioning of N2 is main-
tained in 6, as observed in its complex with TmGH1 (Figure 2a). 
However, and in contrast to 5, 1H-imidazole 6 may undergo 
prototropic tautomerism (Figure 3a). Thus, whilst the overall 
pKAH values of 5 and 6 are similar, the N2 lone pair of 6 may be 
less available for interaction with the glucosidase acid/base, re-
ducing the binding affinity of 6 compared to 5. Protonation of the 
imidazole in turn (either in solution or by proton abstraction from 
the acid/base residue)28 results in positive charge delocalization. 
Resulting charge-charge interactions with enzyme active site 
carboxylates are thought to contribute substantially to enzyme 
binding energy of azole-type inhibitors.29 We calculated the Mul-
liken charge on all atoms for protonated 5 and 6 by DFT. Protona-
tion of the azole ring in 5 produces a G+ charge on the anomeric 
carbon, which is ideally located for a charge-charge interaction 
with a retaining glucosidase active site nucleophile. Conversely, 
protonation of 6 leads to a G+ charge largely delocalized onto the 
apical carbon atom of the imidazole, with the overall G+ charge 
also being less pronounced (Figure 3b). This apical G+ charge is 
located distal from the catalytic nucleophile and thus poorly posi-
tioned for charge-charge interactions, which may explain the 
reduced binding enthalpy observed in ITC for gluco-1H-
imidazoles 6 compared to 5. The small upwards shift and in-
creased imidazole B-factors, observed in crystal structure com-
plexes of 6 compared to 5 is also consistent with a weaker charge-
charge interaction of the imidazole portion of 6 with the enzyme 
catalytic nucleophile. Interestingly, in contrast to neutral 6, glu-
coimidazole 5 also contains a significant G+ character (+0.306 
Mulliken charge) on the anomeric carbon in its neutral state (see 
SI). 
In conclusion, we have described a new class of competitive ȕ-
glucosidase inhibitors: the 1H-gluco-azoles. The synthetic route is 
flexible regarding substituents on the imidazole ring, and can 
likely be transferred to configurational isomers by applying this 
route to configurational isomers of cyclohexene 10.30 Our com-
pounds resemble to some extent the 1H-imidazoles reported by Li 
and Byers31, and Field et al.,32 whose simple, achiral molecules 
inhibit several glucosidases as well, though likely by a different 
mode of action. 1H-Imidazole 6 appeared a poorer inhibitor than 
compound 5, and we hypothesize this is caused by delocalization 
Figure 2. (a) Gluco-1H-imidazole 6 in complex with TmGH1,
with direct H-bonding interactions shown. (b) Overlay of 5 (pink)
and 6 (cyan) within the TmGH1 active site (chain B from each
structure). (c) Gluco-1H-imidazole 6 in complex with TxGH116. 
(d) Overlay of 5 (salmon) and 6 (blue) within the TxGH116 acti-
ve site. Electron densities are REFMAC maximum-likelihood/ıA
weighted 2FoíFc contoured to 0.38 (TmGH1) or 0.48 (TxGH116)
e-/Å3. 
Figure 3. Interactions of gluco-1H-imidazole 6 and classical 
glucoimidazole 5 with the catalytic residues. (a) Prototropic 
tautomerism of 6. (b) Positive charge is delocalized onto the
apical carbon in protonated 6. (c) In 5, positive charge is delo-
calized onto the anomeric equivalent carbon, ideally located for
charge-charge interaction with the nucleophile residue. Mulliken 
charges are annotated in red. 
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of the lone pair on the nitrogen atom due to tautomerism and/or 
impaired G+ charge development at the anomeric center. Introduc-
tion of an alkyl substituent on the 1H-imidazole ring (as in 7) as 
well as deletion of the methylene carbon (as in 9) yielded potent 
competitive inhibitors of the human lysosomal glucosylcerami-
dase GBA1, selective over human cytosolic GBA2 and GCS. 
These and related compounds we believe have potential to be 
developed into pharmacological chaperone candidates for Gau-
cher disease and perhaps also neuropathological disorders (in 
particular, Parkinsonism) that are characterized by partial defi-
ciency in GBA.33,34 
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